BiomX Inc. Files 8-K: Other Events Reported

TL;DR

BiomX filed an 8-K for 'Other Events' - need more info.

AI Summary

BiomX Inc. filed an 8-K on December 11, 2025, reporting an 'Other Events' item. The company, formerly known as Chardan Healthcare Acquisition Corp. until April 30, 2018, is incorporated in Delaware and headquartered in Ness Ziona, Israel. The filing does not disclose specific details about the 'Other Events' but is a standard SEC filing.

Why It Matters

This filing indicates a material event has occurred for BiomX Inc., requiring disclosure to investors. However, the lack of specific details in this initial report necessitates further investigation.

Risk Assessment

Risk Level: medium — The filing itself is routine, but the 'Other Events' category can encompass significant, undisclosed developments that pose a risk to investors.

Key Players & Entities

• BiomX Inc. (company) — Registrant
• Chardan Healthcare Acquisition Corp. (company) — Former company name
• December 11, 2025 (date) — Date of report
• 22 Einstein St. (address) — Principal Executive Offices
• Ness Ziona, Israel (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value PHGE NYSE American Indi

Filing Documents

• ea0269336-8k_biomx.htm (8-K) — 27KB
• 0001213900-25-120668.txt ( ) — 189KB
• phge-20251211.xsd (EX-101.SCH) — 3KB
• phge-20251211_lab.xml (EX-101.LAB) — 33KB
• phge-20251211_pre.xml (EX-101.PRE) — 22KB
• ea0269336-8k_biomx_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. As previously reported, on December 8, 2025, BiomX Inc. ("BiomX" or the "Company") announced the discontinuation of its ongoing Phase 2b study (the "Study"), which was primarily conducted by the Company's wholly owned Israeli subsidiary, BiomX Ltd. After evaluating the projected timelines and resources required to proceed with an alternative dosing strategy recommended by the Data Monitoring Committee, the Company determined that these requirements exceeded its available resources, resulting in the decision to discontinue the program. On December 11, 2025, following the discontinuation of the Study and in light of the Company's limited financial resources, the board of directors of BiomX Ltd. resolved to approve and authorize the filing of an application to commence insolvency proceedings for BiomX Ltd. in accordance with the Israeli Insolvency and Financial Regulation law 5778-2018. The Company is evaluating its strategic options while continuing to own its BX011 program for diabetic foot infections, which is being conducted by Adaptive Phage Therapeutics, Inc., the Company's other subsidiary.

Forward-Looking Statements

Forward-Looking Statements This Current Report contains express or implied "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "may," "anticipate," "estimate," "would," "positioned," "future," and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, when BiomX refers to its focus on its BX011 program and prospects of its development, the insolvency proceedings for BiomX Ltd., evaluation of strategic options and the sufficiency of financial and other resources, it is using forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management's current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX's control. These risks and uncertainties include, but are not limited to, changes in applicable laws or regulations; the possibility that BiomX may be adversely affected by other economic, business, and/or competitive factors, including risks inherent in pharmaceutical research and development, such as: adverse results in BiomX's drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies and early clinical trials may not be replicated in later clinical trials, BiomX's ability to enroll patients in its clinical trials, and the risk that any of its clinical trials may not commence, continue or be completed on time, or at all; decisions made by the FDA, and other regulatory authorities; decisions made by investigational review boards at clinical trial sites

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOMX INC. December 11, 2025 By: /s/ Jonathan Solomon Name: Jonathan Solomon Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR